Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Michael Powell, Ed Mathers, Elaine Jones, Tim Freeborn

Premium

Mirna Therapeutics has appointed a number of new board members following its recent Series C financing round (see related story, this issue).

Joining the board are Michael Powell, a general partner at Sofinnova Ventures, and Ed Mathers, a partner at New Enterprise Associates.

New additions to the board of directors also include Elaine Jones, executive director for venture capital/worldwide business development at Pfizer.


Silence Therapeutics has named Tim Freeborn as its finance director.

Freeborn joins Silence from Xcap Securities, where he was head of research.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more